The Investor Pitch for an Adjuvant Company

An adjuvant is an ingredient, not a medicine. That one fact shapes the whole business plan. Regulators do not license an adjuvant on its own. As summarised in an FDA basis-for-action document for the 2017 approvals, the adjuvant is a constituent of the licensed vaccine, and the vaccine formulation in full is what gets tested in trials and licensed. An adjuvant cannot be added or removed, and its amount cannot change, without a supplement to the vaccine license. Your customer therefore has to put your molecule into their regulatory filing, and every investor you meet will ask one question first: who has already agreed to do that?

Below is a fill-in pitch paragraph built for this structure. It leads with the partnership, then the supply position, then the data, because that is the order in which a biotech investor loses interest. Replace the bracketed items with your own numbers.

The antigen-sparing line matters more than founders expect. Dose sparing is the only adjuvant benefit a procurement team can price. Better immunogenicity is a scientific claim. Fewer micrograms of recombinant antigen per dose is a line item. The financial model you attach to this pitch should convert every efficacy result into either grams of antigen saved, doses made available from a fixed manufacturing run, or a lower number of boosters per patient.

What an investor checks in the first ten minutes

• The comparator: an adjuvant study with no head-to-head arm against aluminium salts, AS01-type, CpG 1018 or Matrix-M is treated as anecdote
• The supply chain: whether each input can be made at GMP grade in batches that cover at least a Phase 2 programme
• The partner: a named vaccine developer, even at material-transfer stage, outweighs a third animal study
• The patent estate: composition-of-matter claims on the molecule or formulation, and freedom to operate around the incumbents
• The exit path: adjuvant platforms sell through licensing, supply agreements or acquisition by a vaccine maker or excipient group, rarely through an independent product launch

If you want the narrative drafted by people who write biotech investor documents every week, the Research + Content package covers the pitch, the market section and the data citations. Related reading: our biopharmaceutical business plan template covers the wider financing structure for drug developers.

How Big the Adjuvant Market Really Is

Published estimates of the vaccine adjuvants market disagree by a factor of six. That is not a rounding problem. It is a definition problem, and your business plan has to pick a definition and defend it. Some analysts count only the adjuvant ingredient sold to vaccine manufacturers. Others count the full revenue of adjuvanted vaccines. A plan that quotes the biggest number without saying which one it is will be marked down by any investor who has read two reports.

At the conservative end, MarketsandMarkets values the market at $0.70 billion in 2024, rising at 6.5% a year to $0.96 billion in 2029. A September 2026 release puts it at $3.1 billion by 2031. Three of these reports sit near $1 billion for the ingredient alone, and the others fold in broader formulation revenue.

Which number belongs in your plan

For a company selling an adjuvant ingredient, the serviceable market is the ingredient line, so the $0.7B to $1.25B band is the defensible base. For a company that expects to take a royalty on adjuvanted vaccine sales, the relevant pool is the revenue of the vaccines carrying your adjuvant, and the plan should model that bottom-up, one named vaccine at a time. State both and say which one drives the forecast. The sensible approach is to build the revenue model on named programmes and use the top-down figure only as a sanity check on share.

The demand drivers cited most often across these reports are the same: adult and older-adult vaccination (shingles, respiratory), pandemic preparedness, therapeutic cancer vaccines, and the shift from aluminium-only formulations toward newer systems. The commercial proof point for the newer systems is concrete. Novavax licensed its adjuvanted COVID-19 vaccine to Sanofi in May 2024 in a deal worth up to $1.2 billion, with $500 million upfront and up to $700 million in milestones, and the agreement included non-exclusive rights for Sanofi to use Matrix-M in other vaccine products (Pharmaceutical Technology). That is the template for how an adjuvant gets monetised: a vaccine maker pays for access, and the adjuvant owner keeps manufacturing and supply.

Who the competitors actually are

Four names appear in nearly every market report. GSK owns the AS01 adjuvant system, which pairs the TLR4 agonist MPL with the saponin QS-21 in a liposome. Dynavax owns CpG 1018, a 22-mer phosphorothioate oligonucleotide, used in Heplisav-B. Novavax owns Matrix-M, a saponin-based nanoparticle adjuvant. Croda, through its 2020 acquisition of Avanti Polar Lipids, sells alum-based and liposomal adjuvants and runs a CDMO service under Croda Pharma. In 2017 both Shingrix and Heplisav-B were licensed with novel adjuvants, which is why that year is the usual reference date for the modern commercial era.

A start-up competes against these four on a narrow front. You are not going to out-spend GSK. You are offering one of three things: a molecule that avoids a supply bottleneck the incumbents have, a profile that suits a vaccine type they do not serve, or a platform cheap enough to make adjuvanted vaccines viable in markets where they are priced out today. Pick one and let the rest of the plan prove it.

Capital Required to Reach an IND

The right unit of account for this business is not "startup cost". It is the cash needed to reach the first regulatory filing that includes your adjuvant, usually an IND or a clinical trial application for an adjuvanted candidate run with a partner's antigen. The figures below are Avvale modelling ranges for a small synthetic or semi-synthetic adjuvant company, built from typical contract research and CDMO quotes. They are planning estimates, not published prices, and you should replace them with written quotes before a bank or investor sees the plan.

The largest swing factor is raw material, and the clearest example is QS-21, the saponin fraction behind several licensed systems. It comes from the bark of Quillaja saponaria trees, and the useful fractions come only from trees more than ten years old. Trade commentary cited by the IBSA Foundation puts the price at above $100,000 per gram, with roughly 1 mg of saponin in each vaccine dose. Desert King, the San Diego supplier that dominates purified saponin for vaccines, has been reported to offer GMP QS-21 in 100 mg quantities, with batch sizes near 15 grams and annual output in the hundreds of grams.

Worked example: what a gram of saponin means for dose economics

At 1 mg per dose, one gram covers 1,000 doses. At the quoted $100,000 per gram, the saponin alone costs about $100 per dose before formulation, fill and quality testing. A 15-gram batch covers 15,000 doses, and a year of supplier output at, say, 300 grams covers 300,000 doses. Compare that to a pandemic-scale programme that wants 100 million doses: it would need 100 kilograms of saponin, roughly 330 years of that output. This arithmetic, using the cited figures, is the entire commercial argument for synthetic and semi-synthetic alternatives, and a plan for a company selling one should put this calculation on page one of the market section.

Funding routes that fit this business

• NIAID SBIR contracts (US): Topic 140, Adjuvant Discovery and Down-Selection, pays up to $300,000 a year for two years in Phase I and $500,000 a year for up to three years in Phase II. Topic 142, Adjuvant Development for Vaccines, pays $300,000 a year in Phase I and up to $1,000,000 a year in Phase II with justification, with one to three awards expected. Details are on the SBIR.gov topic page and NIAID's Adjuvant Development Program.
• CEPI-style advance-manufacturing loans: CEPI agreed an interest-free, forgivable loan of up to $99.0 million to Dynavax for CpG 1018 manufacturing in 2020, later expanded to $176.4 million in total (Dynavax, CEPI). The loan is forgiven if the partner vaccines fail and the reserved adjuvant has no other use, which is a structure worth copying in a smaller form when negotiating with a vaccine developer.
• Specialist venture capital: Adjuvant Capital and RA Capital co-led VitriVax's $17.25 million Series B in 2025, and Adjuvance Technologies has raised about $13.4 million over four rounds, according to Crunchbase. Those two numbers are a realistic range for a platform company at Series A scale.
• UK routes: Innovate UK grants, Start Up Loans up to £25,000 for founder living costs, and SEIS/EIS for early equity. A pre-revenue biotech with a UK base can use SEIS for a first £250,000 and EIS afterwards, subject to HMRC advance assurance.

For a first raise, the SBIR route is the better opening move than it looks. A Phase I award does not fund an IND, but it funds the head-to-head data that makes a seed round possible, and it does so without giving up equity. If you want the funding sections of your plan benchmarked against real small-business lenders and grant panels, our free business plan template is the starting structure and the Bespoke package builds the full model.

How Adjuvant Companies Earn Money

There are four revenue lines in this business and most plans mix them up. Separating them is what makes the forecast believable.

1. Evaluation fees: a vaccine developer pays to test your adjuvant with their antigen. Typical range is low six figures per programme, and it is revenue only in the sense of cost recovery.
2. Option and licence fees: the payment that turns an evaluation into a right to include your adjuvant in a filing. These are lumpy and milestone-linked.
3. Supply revenue: the adjuvant sold per dose or per gram once the vaccine is approved. This is the recurring line and the one with real margin.
4. Royalties: a percentage of net vaccine sales, common where the adjuvant is a defining component.

The Novavax-Sanofi agreement shows the large-end structure: $500 million upfront and up to $700 million in milestones. At the other end, Dynavax's CpG 1018 is a useful small-scale reference. The company's 2021 filings show $26.7 million of adjuvant revenue from Medigen, a Taiwanese vaccine developer, in a single year (see the FY2021 Form 10-K). That figure came from supplying a vaccine in a pandemic year, so treat it as a ceiling for early supply revenue, not a base case.

Unit economics you can defend

Below is a simple model for a synthetic adjuvant sold at a cost-plus price. These are illustrative assumptions for a plan, not market data.

Ten million doses is a modest figure. A single national adult-vaccination programme can exceed it in a year. The point of the table is to show an investor that you know where the margin lives and where it leaks. A common error is to model an adjuvant at pharmaceutical-style gross margins of 85% or more. A cost-plus supply price tied to a vaccine maker's cost of goods will look more like 50% to 65%, and the plan should say so.

What drives the price you can charge

Procurement teams at vaccine makers think about adjuvant price relative to antigen cost. If your adjuvant lets them cut recombinant antigen from 50 micrograms to 15 micrograms per dose, the saving per million doses depends on what their antigen costs to make. A subunit antigen at $4 to $10 per dose of manufacturing cost means a 70% antigen reduction saves $2.80 to $7.00 per dose. That sets a ceiling on what the adjuvant can cost before the economics stop working for them, and it is the number to negotiate against. Put the saving, not your own cost, at the centre of the pricing section.

Seasonal revaccination matters too. MarketsandMarkets commentary notes that recurring annual or seasonal revaccination can turn the adjuvant from an embedded formulation cost into a repeat-revenue lever across adult respiratory, shingles and geriatric portfolios. Model your volumes by named vaccine and by year of launch, and discount for the probability that each programme reaches approval. Late-stage vaccine failure rates are high enough that unweighted forecasts lose credibility.

Four Adjuvant Platforms Compared

Choosing a platform is the first decision in the plan, and it defines your capital needs, supply risks and competitors. This table compares the four categories investors see most often. The named examples are real products; the cost and risk columns are Avvale's qualitative assessments.

A start-up in the first row will struggle because alum is cheap and ubiquitous. A start-up in the last row has the best fundraising story, since it addresses the saponin supply problem, but must prove itself clinically against products with licensed track records. The second and third rows are crowded with well-funded owners, so a new entrant there needs a differentiated molecule rather than a copy.

Where the CDMOs and suppliers sit

• Croda Pharma (including Avanti): lipids, alum and liposomal adjuvants, with a GMP catalogue and custom CDMO projects. Croda signed a five-year lipid supply agreement with Pfizer, which shows the capacity is real.
• Desert King International: purified Quillaja saponins and GMP QS-21, headquartered in San Diego.
• Dynavax: sells CpG 1018 to third-party vaccine developers as a supply business as well as using it in its own products.
• Novavax: Matrix-M is licensed in combination with specific vaccines rather than sold as a standalone ingredient.

A good plan names which of these is a supplier, which is a competitor and which is both. Dynavax is the instructive case: it is simultaneously a rival adjuvant owner and the largest proof that a supply business can work. Your plan can cite that dual role in the competitor analysis.

Structuring the first partner deal

The first partnership sets the template for everything after it, so the plan should describe the intended structure rather than leave it as "to be negotiated". A sensible sequence has four steps. First, a material transfer agreement that lets the partner test your adjuvant with their antigen in animals, usually for a fee that covers your formulation and shipping costs. Second, a joint study design that fixes the comparator arms and the success criteria in advance, so that nobody argues about interpretation afterwards. Third, an option agreement, with a payment in the low six figures, that reserves exclusivity for a defined antigen class for 12 to 18 months. Fourth, a licence and supply agreement triggered by a clinical go decision, containing the per-dose price, minimum volumes and the royalty rate.

Three clauses decide how much value you keep. Exclusivity should be limited to an antigen class or indication, not to the whole adjuvant, or you will starve your own pipeline. Improvement ownership should stay with you for changes to the adjuvant and with the partner for changes to the antigen. Supply rights should include a right to second-source the antigen if the partner stops, because a stranded adjuvant with a locked exclusive is the worst outcome for a small company. The Novavax and Sanofi agreement is instructive here: Sanofi received a sole licence for combination with its flu vaccines but only non-exclusive rights for other products, which left Novavax free to commercialise Matrix-M elsewhere.

Timeline from founding to first-in-human

A realistic timeline for a company starting from a university lab result is 24 to 30 months. The first six months go to formulation screening and the first animal immunogenicity studies, alongside company formation and the university licence. Months six to twelve cover analytical method development, a non-human primate study and the first partner material transfer agreement. Months twelve to eighteen are the GMP engineering run and first clinical lot, which is the longest single item because CDMO slots are scheduled months ahead. Months eighteen to twenty-four cover GLP toxicology, the pre-IND meeting and the clinical trial application. Delay in any one of the CDMO booking, the toxicology start or the partner agreement pushes the entire plan back, so the Gantt chart in your plan should show these three as the critical path and state the float on each.

Investors also read the timeline as a measure of burn. A plan that reaches first-in-human at month 26 with $5.4 million spent looks different from one that reaches it at month 34 with $7.8 million spent, even if the science is identical. Show the monthly cash curve and mark the point at which each funding source, whether SBIR award, seed tranche or partner payment, lands.

Regulatory Path: FDA, EMA and MHRA

The regulatory strategy for an adjuvant company is indirect. You do not file for approval of the adjuvant. You support a customer's filing and sometimes hold a master file. Plans that describe an "FDA approval process for our adjuvant" misunderstand the structure and lose credibility with biotech investors who know it.

United States

• Regulator: Center for Biologics Evaluation and Research (CBER), which reviews vaccines. The adjuvant is reviewed as part of the vaccine biologics license application.
• Constraint: the adjuvant is licensed as a constituent of the vaccine. Adding, removing or changing its amount requires a supplement to the vaccine license (FDA summary basis for regulatory action, November 2017).
• Your filing: a drug master file or equivalent CMC dossier that the vaccine sponsor references, covering identity, purity, potency, stability and manufacturing controls.
• Precedent: Shingrix and Heplisav-B were both licensed in 2017 with novel adjuvants, so the path is established but narrow.

European Union

The EMA's guideline on adjuvants in vaccines for human use remains the reference for quality requirements. The EMA states it will not update the guideline because its clinical and non-clinical sections have been superseded by the clinical evaluation guideline for new vaccines and the WHO non-clinical guideline, but the quality section remains valid. One detail that affects business models: a substance given separately or at a different time from the antigen is not an adjuvant under the guideline and is classed as an immunomodulator, which changes the data package. If your product is designed to be administered on its own schedule, say so and plan the regulatory route accordingly.

United Kingdom

The MHRA authorises clinical trials of adjuvanted vaccines under its clinical trials for medicines authorisation route, and current application fees are listed on the MHRA fees page. In practice a UK adjuvant company runs a first-in-human study with a partner's antigen under a single clinical trial authorisation. The business plan should show which party is the sponsor, because it determines who carries the insurance, the pharmacovigilance duties and the data ownership. A UK base also gives you access to the Stevenage Bioscience Catalyst campus and Harwell, both useful for lab space without a long lease.

Other jurisdictions to plan for

If you expect your adjuvant to be used in vaccines destined for lower-income markets, the WHO prequalification process and CEPI's funding conditions shape your manufacturing and pricing commitments. CEPI's Dynavax loan carried a forgiveness clause tied to vaccine programme success, which is the kind of term to anticipate. For vaccines manufactured in India, Korea or China, local regulators will also review your documentation, and a master file prepared to ICH standards simplifies this.

Non-regulatory legal items

• Freedom to operate: saponin, TLR agonist and liposome patents are dense. Budget $40K to $120K for a proper opinion before the seed round closes.
• Material transfer agreements: standard before any partner evaluation, with strict rules on who owns improvements.
• University licences: many adjuvant start-ups spin out of academic labs. Expect a royalty of 2% to 5% and equity of 5% to 15% to the institution, then model both.
• Insurance: clinical trial liability, product liability and cyber cover are all expected by a CDMO or partner.

Mistakes That Sink Adjuvant Plans

1. Quoting the largest market figure without a definition. With published 2025 numbers from $0.87 billion to $5.26 billion, an unlabelled "$5 billion market" tells a reader you did not check. State which definition you use and why.
2. Treating the adjuvant as a standalone product. It cannot be licensed alone. A plan with a "launch" date for an adjuvant on its own has missed how the product reaches patients.
3. Skipping the head-to-head arm. Studies against saline or antigen alone show that an adjuvant works. Studies against alum, AS01-type or CpG 1018 show that yours is worth buying.
4. Ignoring the supply chain. A promising molecule that needs a precursor available in gram quantities cannot support a Phase 3 programme. Name the supplier and the batch size for each input.
5. Pharmaceutical margins on an ingredient business. Adjuvants are priced against the vaccine maker's cost of goods. Margins of 50% to 65% are credible. Margins above 80% are not.
6. No plan for the partner's failure. Most vaccine candidates fail. Show what you do with reserved manufacturing capacity if the first partner exits, as CEPI's forgivable loan structure recognised.

Sample Plan Extract

A faded preview of how the executive summary reads in a finished adjuvant plan. The company is a composite; the structure is what the template gives you.

The paid packages go further. The Research + Content package writes the market, competitor and regulatory sections with citations, and the Bespoke package adds a five-year Excel model with scenario tabs for partner success and failure.

What Is in the Template

Every Avvale business plan template includes these sections, pre-structured for your industry. For adjuvant companies we recommend giving extra weight to the sections marked below.

• Executive Summary: the pitch paragraph above fits here, written to hold attention in 60 seconds
• Company Overview: legal structure, university licence terms, ownership and founding story
• Industry Analysis (heavy): market definition, the four incumbent adjuvant owners and your chosen platform class
• Customer Analysis (heavy): named vaccine developers, their antigen cost structure and their decision process
• Competitor Analysis: head-to-head data against AS01, CpG 1018, Matrix-M and alum
• Marketing Plan: scientific conferences, partner outreach and publication strategy rather than consumer channels
• Operations Plan (heavy): CDMO selection, raw-material sourcing, batch sizes and quality release
• Management Team: founders, scientific advisory board and planned CMC and regulatory hires

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and startup capital requirements. For adjuvant companies we build it around programme-level revenue and probability-weighted milestones. Related template: animal and veterinary vaccines, where adjuvants are sold into a faster regulatory environment.

Frequently Asked Questions

Useful Links & Resources

• Biotech business plan template
• Clinical trials business plan template
• Facebook
• Instagram
• LinkedIn
• YouTube